MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.

She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.

MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.

The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.

How Metal Objects Interact with MRI Fields?

On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."

The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.

This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.

A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.

These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.

Preventing MRI-Related Incidents

Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:

• Patients are interrogated about implants, recent surgery or exposures at work related to metals.
• Radiologists sometimes use handheld metal detectors to search for hidden items.
• People who work with metal, like welders or machinists, will need additional testing to detect microscopic metal fragments within soft tissues or eyes.

The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.

It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.

In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.

This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.

A US woman undergoing routine knee surgery at a Nashville hospital was left paralyzed following a medical mistake in which potassium was reportedly given instead of the intended anesthetic.

Speaking to the media, her daughter-in-law said that while the 72-year-old’s knee replacement went well, potassium administered during spinal anesthesia instead of bupivacaine has left her paralyzed.

“The joint replacement went wonderfully. Her knee is great. The rest of her is not,” daughter-in-law Kristina Dorton was quoted as saying by WSMV.com.

What Went Wrong During the Knee Surgery?

On August 14, her mother-in-law went in for a routine knee replacement at Ascension Saint Thomas Hospital Midtown. Everything appeared normal for the healthy 72-year-old until the surgical team realized that she had been given the wrong medicine during spinal anesthesia.

“It was supposed to be the anesthetic. It was supposed to be Bupivacaine, and it was potassium, and we don’t know what quantity,” Dorton said.

According to Dorton, when her mother-in-law woke up from surgery, she was sent to the intensive care unit. While the knee replacement was successful, her family is worried that she may never be able to feel her knee or any part of her lower body again.

“Currently, she has zero feeling, movement, or response to pain from her breastbone down. We don’t know what recovery looks like or if there is recovery,” Dorton said.

Four Patients Reportedly Impacted

According to media reports, the woman was not the only patient affected. An investigation found that as many as four patients were impacted by similar “events” involving the administration of the wrong medication at Ascension Saint Thomas Hospital Midtown.

“Our hearts are with the four patients and their families impacted by this event. On behalf of our leadership and care teams, I am deeply sorry for the harm caused to our patients,” Dr. Shubhada Jagasia, president and CEO of Ascension Saint Thomas Hospital’s Midtown, said in a statement.

However, hospital officials did not confirm whether the other patients also received potassium instead of the intended anesthetic, stating that they would not provide specific clinical details to protect patients’ privacy.

While Jagasia said the hospital is ensuring that affected patients have access to the resources and ongoing care they need, Dorton said treatment aimed at reversing her mother-in-law’s paralysis has not worked.

“This is life-changing. You don’t come out of this without some type of life-altering, catastrophic deficit,” Dorton said.

“We just are hoping that publicizing this gets some sort of genius somewhere that knows what to do… Time is of the essence here for recovery,” Dorton added.

When Can Potassium Turn Dangerous?

Potassium is an essential mineral that helps the body function. While it plays important roles in blood pressure regulation, bone health and kidney function, having too much potassium in the blood can lead to serious and potentially life-threatening problems.

Too much potassium in the blood is known as hyperkalemia. Severe hyperkalemia can affect the heart’s electrical activity and cause dangerous abnormal heart rhythms or cardiac arrest.

Potassium is also not used as an anesthetic agent. During medical care, potassium levels must be carefully managed because changes in this electrolyte can significantly affect heart and muscle function.

A personalized mRNA cancer vaccine developed by pharma giants Moderna and Merck has shown promise for patients with melanoma, a potentially deadly form of skin cancer, in a late-stage trial.

The vaccine, called intismeran autogene, or mRNA-4157/V940, is custom-made for each patient using the unique genetic blueprint of their tumor.

The Phase 3 results build on earlier Phase 2b findings and showed that the combination of intismeran and Keytruda reduced the risk of cancer recurrence or death by 49% and reduced the risk of distant cancer spread or death by 59% up to five years.

“These Phase 3 findings represent a pivotal moment for the field of cancer research. For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality,” said Stéphane Bancel, CEO of Moderna.

Trial Shows Longer Cancer-Free Survival

The Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS).

Intismeran autogene in combination with Keytruda demonstrated statistically significant and clinically meaningful improvements in RFS and DMFS compared with Keytruda alone.

The findings were seen in patients with stage IIB, IIC, III, or IV cutaneous melanoma who had undergone complete surgical removal of their cancer and had not previously received systemic therapy.

The companies, however, aim to continue evaluation of other key secondary endpoints, including overall survival.

What Is Intismeran Autogene?

Intismeran autogene is an experimental "neoantigen therapy" that uses specific mutations in a patient’s tumor to train the immune system to recognize and fight cancer cells.

The treatment is designed using a patient’s tumor sample to identify the unique mutational signature, or “fingerprint,” of their cancer and generate an anti-tumor immune response.

Each therapy contains synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient’s tumor.

After administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, helping generate specific T-cell responses against cancer cells.

How Was the Phase 3 Trial Conducted?

• 1,137 patients with high-risk, resected stage IIB-IV melanoma took part in the trial.
• Participants were randomly assigned 2:1 to receive either:
• Intismeran autogene + Keytruda
• Keytruda alone
• Intismeran was given every three weeks for up to nine doses.
• Keytruda was given every six weeks for up to nine cycles, for about one year.
• The trial assessed the safety and effectiveness of the combination compared with Keytruda alone.

Were There Any Safety Concerns?

The safety profiles of intismeran autogene and Keytruda in the trial were consistent with those observed in previously reported studies of the combination. No new safety signals were observed.

“Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer,” said Professor Georgina Long, the study’s principal investigator and medical director of Melanoma Institute Australia.

Long said the results “represent a landmark moment for adjuvant melanoma treatment.”

Hair loss is one of the recent and increasingly discussed concerns among people taking popular weight-loss medicines like Ozempic and Zepbound.

A new study has compared hair loss risk linked with these two drugs to obtain a clear picture of whether one drug is more likely to trigger shedding than the other.

The study, published in the Journal of the American Academy of Dermatology, examined the risk of new-onset hair loss among people taking semaglutide or tirzepatide, the active ingredients in Ozempic/Wegovy and Zepbound/Mounjaro, respectively.

The findings emerge at a time when hair loss due to GLP-1 treatment is widely discussed. Even though the findings indicate, the absolute risk of hair loss due to GLP-1 remains relatively low.

Ozempic Vs Zepbound: Which Drug Poses Higher Risk?

The study compared people who were prescribed semaglutide and tirzepatide and looked at newly diagnosed hair loss. The researchers found an association between use of both medications and hair loss, including conditions like telogen effluvium, a form of temporary shedding that can occur after a major physical or metabolic stress.

However, the researchers say that the findings not be interpreted as proof that either drug directly damages hair follicles. The study was based on electronic health data, which helped researchers identify an association but could not establish that the medication itself was the cause of hair loss.

Also read: Nestlé Customizes Drinks For Ozempic, Wegovy Consumers: What Are Protein And Nutrition Needs of GLP-1 Users?

Why Can Weight-Loss Drugs Cause Hair Shedding?

One of the leading explanations suggests that the hair loss has more to do with the rapid change in metabolic health which helps with the weight loss. Researchers have not found evidence that the drug directly attacks the hair follicles.

When the body undergoes a sudden metabolic change, more hair follicles can prematurely enter the resting phase of the hair-growth cycle. Several months later, those hairs can shed. This effect is known as telogen effluvium.

Reduced food intake can also mean some people consume less protein, iron and other nutrients which are essential for for healthy hair growth. These factors could contribute to shedding during a phase of major weight loss.

Previous clinical data have reported hair loss in around 3% of adults taking Wegovy compared with 1% taking placebo, while Zepbound trials reported hair loss in about 4%-5% of users compared with 1% with placebo.

Also read: Paris Jackson Undergoes ‘Painful’ ECT for Depression: Can Electroconvulsive Therapy Reduce Suicide Risk?

Temporary Hair Loss Due To Metabolic Shift

Telogen effluvium is generally a temporary form of hair shedding. Hair follicles remain intact, meaning they can return to their normal growth cycle once the rapid weight loss stabilises.

Hair shedding may become noticeable several months after weight loss begins, rather than immediately after starting the medication. Regrowth can then take several additional months.

However, not every case of hair loss during GLP-1 treatment is necessarily telogen effluvium. Other forms of alopecia can have different causes and require different treatment.

The new findings come amid growing scrutiny of hair loss as a potential adverse effect of GLP-1 medicines.

A separate large study published in The BMJ in July 2026 also found that adults with type 2 diabetes taking GLP-1 receptor agonists had a slightly higher risk of alopecia compared with people taking other diabetes medicines.

Researchers have stressed that more research is needed to understand whether the medicines themselves contribute to hair loss or whether the shedding is related to rapid weight loss and metabolic or nutritional changes.